Google's Agent Development Kit for Java reached 1.0, introducing integrations with new external tools, a new app and plugin ...

Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. Dany Lepage discusses the architectural ...

SUNNYVALE, Calif.--(BUSINESS WIRE)--Azul, the trusted leader in enterprise Java for today’s AI and cloud-first world, today warned enterprises of a growing Java application modernization crisis driven ...

The Food and Drug Administration has refused to review Moderna's application for its seasonal flu vaccine, the company announced on Feb. 10, marking the latest setback for the development of ...

Correction: This story was updated to clarify a statement given by Department of Health and Human Services spokesperson Andrew Nixon. Moderna said on Tuesday that the Food and Drug Administration (FDA ...

Moderna’s messenger RNA influenza vaccine succeeded in two pivotal clinical trials, but the Food and Drug Administration is refusing to even review the application seeking regulatory approval, telling ...

The U.S. Food and Drug Administration (FDA) refused to consider Moderna’s application for a new flu vaccine using mRNA technology, the company announced Tuesday, a decision that could delay the ...

Feb 10 (Reuters) - The U.S. Food and Drug Administration will not review Moderna's (MRNA.O), opens new tab approval application for its influenza vaccine, the company said on Tuesday, sending its ...

The Food and Drug Administration rejected Moderna’s application for its mRNA-based flu vaccine, the drugmaker said Tuesday. Subscribe to read this story ad-free Get unlimited access to ad-free ...

The US Food and Drug Administration has refused to accept an application from Moderna to review its first mRNA seasonal flu vaccine, the company said Tuesday, in another setback for the technology ...

A new review including over 100 clinical trials has found that no induction method was clearly more effective than low-dose vaginal misoprostol, although some methods were less effective and safety ...

After unsheathing just a few months ago, Ollin Biosciences’ next-gen bispecific antibody cleared more disease faster than Genentech’s Vabysmo for patients with diabetic macular edema (DME) in an early ...